PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015699

GI

Evidence text

Paper-level observation

At days fifteen and seventeen post‐treatment initiation, treatment with StCl‐GI_GII (P = 0.0037 and P < 0.0001) ... induced significantly reduced tumor growth compared to PBS (Figure 6c).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
<
Raw observation
P = 0.0037 vs PBS (day 15); P < 0.0001 vs PBS (day 17)
Normalized measurement
<0.0001
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Homo sapiens
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.